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Frailty, a poorly measured confounder in older patients, can promote treatment in some situations and discour-
age it in others. This can create unmeasured confounding and lead to nonuniform treatment effects over the
propensity score (PS). The authors compared bias and mean squared error for various PS implementations under
PS trimming, thereby excluding persons treated contrary to prediction. Cohort studies were simulated with a binary
treatment T as a function of 8 covariates X. Two of the covariates were assumed to be unmeasured strong risk
factors for the outcome and present in persons treated contrary to prediction. The outcome Y was simulated as
a Poisson function of T and all X’s. In analyses based on measured covariates only, the range of PS’s was trimmed
asymmetrically according to the percentile of PS in treated patients at the lower end and in untreated patients at the
upper end. PS trimming reduced bias due to unmeasured confounders and mean squared error in most scenarios
assessed. Treatment effect estimates based on PS range restrictions do not correspond to a causal parameter but
may be less biased by such unmeasured confounding. Increasing validity based on PS trimming may be a unique
advantage of PS’s over conventional outcome models.
bias (epidemiology); causal inference; cohort studies; confounding factors (epidemiology); epidemiologic methods;
models, statistical; propensity score; research design
Abbreviations: IPTW, inverse probability of treatment weighting; PS, propensity score; RR, rate ratio.
Restriction of treatment comparisons to subjects with a
common range of covariates (e.g., age) or any summary
score of covariates (1) can improve the validity of effect
estimates regardless of the analytic technique used. Such
restriction provides a pragmatic focus on persons for whom
uncertainty regarding the value of treatment is most rele-
vant. In practice, implementation of such restrictions can be
complicated and is rarely done outside of propensity score
(PS) analyses (2, 3).
PS analyses offer some advantages in the context of non-
experimental treatment comparisons. These include a focus
on treatment assignment, improved control of confounding
with scarce outcomes, and the ability to easily match co-
horts on a large number of covariates (3). PS analyses do
not offer any advantages with respect to unmeasured con-
founders, however (4).
Frailty is a plausible explanation for paradoxical treat-
ment effects observed in the elderly (5). Frailty may reduce
the likelihood of a particular treatment if physicians focus
on a patient’s main medical problem and do not initiate
useful therapies for alternative conditions (6). The practi-
tioner may determine that in the presence of competing
risks, a new therapy offers little expected benefit (7). Con-
versely, in patients with short life expectancies, physicians
may be more willing to try therapies with potentially serious
side effects as a last resort. Thus, if mortality is the outcome
of interest, frailty can be a powerful confounder that is
difficult to measure and can either increase or decrease the
likelihood of treatment. Although we describe the problem
using the terminology of pharmacoepidemiology, the issues
are more general and the principles should apply broadly to
any type of epidemiologic study.
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Recent studies have provided examples of strong hetero-
geneity of treatment effect estimates over the PS that may be
explained by confounding due to unmeasured frailty (8, 9).
In one study of the effects of thrombolysis on all-cause in-
hospital mortality among patients with stroke, mortality was
much higher in the 17 stroke patients (out of a total of 212)
who received thrombolytic therapy despite having the low-
est PS for receiving it (41% mortality), in comparison with
the remaining 195 patients (14% mortality) (8). These 17
patients with a very low predicted probability of receiving
treatment may have received it because they were very
frail—that is, as a treatment of last resort.
In another study that addressed the effects of treatment
with biologics on all-cause mortality in patients with rheu-
matoid arthritis, mortality was much higher in the untreated
patients in the highest PS quintile (72/1,000 person-years)
than in the remainder of the untreated patients (11/1,000
person-years) (9). Frailty may also explain this difference,
if the high-risk untreated patients did not receive the treat-
ment that they might have received given their clinical con-
dition because they were deemed too frail by the treating
physician (treatment withheld).
If increases in mortality in a few patients who are treated
contrary to prediction are due to unmeasured frailty, then
treatment effects over the PS will appear heterogeneous, and
excluding some or all of the patients treated contrary to
prediction could reduce unmeasured confounding by this
frailty under the assumption of uniform effects (10). In
theory, if we excluded all patients with unmeasured frailty,
the resulting treatment effect estimate would not be biased
from unmeasured confounding by frailty. In practice, ex-
cluding all such patients will be impossible. Excluding in-
creasing proportions of those treated contrary to prediction,
however, would increase internal validity at the price of not
being able to describe precisely the population to which the
treatment effect estimate would apply (11, 12). In other
words, the treatment effect that is estimated would not be
a causal parameter even when implementing the PS in a way
that should produce a causal estimate (13). If, contrary to
this assumption, treatment effect heterogeneity is real and
not due to unmeasured confounding, then excluding some
patients will affect the generalizability of the results.
Our aim in this simulation study was to compare bias and
mean squared error in the treatment effect estimates for
varying degrees of asymmetric restriction of the PS distri-
bution under the assumption of the presence of unmeasured
frailty that leads to ‘‘last resort’’ treatment, ‘‘treatment with-
held,’’ or both. We analyzed the data using a variety of
methods to control for confounding using PS’s.
MATERIALS AND METHODS
Simulation
To simulate confounding by frailty in persons who are
treated contrary to prediction, we used a 2-step process to
define covariates (see Figure 1). We started with 3 dichoto-
mous covariates, X1, X2, and X3, each with a prevalence of
0.2, and 3 continuous covariates, X4, X5, and X6, each with
a mean of 0 and unit variance. All covariates were indepen-
dent of one another. We then calculated the predicted prob-
ability of the dichotomous intended treatment T based on
these 6 ‘‘measured’’ covariates and the covariate-treatment
associations presented in Table 1, using a logistic model:
pðT jX1 --X6Þ ¼ ð1 þ expðða0 þ a1X1
þ a2X2 þ a3X3 þ a4X4 þ a5X5
þa6X6ÞÞÞ1: ð1Þ
We used this probability of intended treatment to assign 2
additional dichotomous covariates. One, X7, was defined as
most likely to be present when the intended treatment
was least likely. X7 was set to 1 (present) when a random
uniform number was less than or equal to [c  p(TjX1–X6)]
and set to 0 otherwise. Thus, observations with a probability
of intended treatment close to 0 would be most likely to
have X7 ¼ 1. The second covariate, X8, was likely to be
present when the intended treatment was most likely. X8
was set to 1 (present) when a random uniform number
was less than or equal to [p(TjX1–X6)  d], absent otherwise.
Thus, observations with a probability of intended treatment
close to 1 would be most likely to have X8 ¼ 1. The values
for c and d were chosen to result in a low prevalence of both
X7 and X8 (see Table 1). We assumed a low prevalence for
persons treated contrary to prediction because of the empir-
ical examples.
Based on these 8 covariates (i.e., the ‘‘measured’’ cova-
riates X1–X6 and the ‘‘unmeasured’’ covariates X7 and X8),
we then recalculated the probability of actual treatment,
again using a logistic model:
pðT jX1 --X8Þ ¼ ð1 þ expðða0 þ a1X1
þ a2X2 þ a3X3 þ a4X4 þ a5X5
þa6X6 þ a7X7 þ a8X8ÞÞÞ1: ð2Þ
T Y
X1 X2 X3 X4 X5 X6
X7 X8
p(T|X1 –X6)
Figure 1. Conceptual diagram of a simulation study depicting treat-
ment (T) and outcome (Y) as a function of measured covariates (X1–
X6) and unmeasured covariates (X7 and X8). The solid lines represent
causal associations, and the dashed lines represent noncausal asso-
ciations used in the 2-step simulation process to mimic treatment
contrary to prediction by measured covariates (X1–X6).
844 Stürmer et al.
Am J Epidemiol 2010;172:843–854
The actual treatment Twas then assigned on the basis of this
probability using a random uniform number. Finally, the ex-
pected number of disease outcomes Yover a fixed follow-up
time interval was derived from all 8 covariates and the treat-
ment T using a log-linear model:
EðY jT ;X1 --X8Þ ¼ expðb0 þ b1X1 þ    þ b8X8 þ bTTÞ:
ð3Þ
The number of outcomes Y was assigned using a random
number from a Poisson distribution based on this expected
value. The Poisson outcome and the log-linear outcome
model were chosen because the incidence rate ratios obtained
are collapsible under exchangeability (14) and therefore al-
low direct comparisons between the analytic strategies (15).
The range of values covered in the simulation study is
presented in Table 1. The 6 measured covariates X1–X6 were
associated only with treatment (X1 and X4), associated only
with outcome (X2 and X5), or associated with both treatment
and outcome (X3 and X6). X7 was strongly positively asso-
ciated with both actual treatment and outcome (or not),
mimicking frailty that leads to ‘‘last resort’’ treatment. X8
was strongly inversely associated with actual treatment and
positively with outcome (or not), mimicking frailty that
leads to ‘‘treatment withheld.’’ The parameter value for
a0 in equation 2 was chosen to result in a prevalence of T
of approximately 0.2 or 0.05, the one for b0 in equation 3 for
an incidence of approximately 0.1 per observation over
a fixed follow-up time in the untreated. For each scenario
or parameter constellation, we simulated 1,000 closed
cohort studies with n ¼ 10,000.
Analysis
PS estimation and implementation. We first estimated
PSX1–X6 based on the measured covariates X1–X6 using
logistic regression. The treatment-outcome incidence rate
ratio controlling for confounding by the measured X’s was
estimated using log-linear models and 5 different methods
to implement PSX1–X6: modeling, stratification assuming
uniform effects, stratification not assuming uniform effects,
matching, and weighting (4).
We first estimated the rate ratio based on treatment and
PSX1–X6 as a continuous covariate, not to encourage this PS
implementation but because it is widely used in medical
research (16). We then stratified the study population into
5 equal-sized strata of PSX1–X6 based on the overall (mar-
ginal) distribution of PSX1–X6. We used 5 strata because that
number of strata has been shown to be sufficient to remove
most confounding (17) and thus has become a widely used
approach in stratifying PS’s (16). We estimated the rate ratio









X1 0.2 2.0 a1 1, 2 1.0 b1 3
X2 0.2 1.0 a2 1, 2 2.0 b2 3
X3 0.2 0.2 a3 1, 2 0.2 b3 3
X4 Continuous (0, 1) 1.5 a4 1, 2 1.0 b4 3
X5 Continuous (0, 1) 1.0 a5 1, 2 1.5 b5 3
X6 Continuous (0, 1) 0.5 a6 1, 2 0.5 b6 3
X7 0.01
e,f 1, 10 a7 2 1, 10 b7 3
X8 0.01
f,g 1, 0.1 a8 2 1, 10 b8 3
T 0.2, 0.05f a0 2 2.0 bT 3
Y 0.1f (incidence rate
in untreated)
b0 3
Abbreviations: OR, odds ratio; RR, rate ratio.
a Parameter values are chosen to represent a study with both prevalent and rare treatment and
a low incidence of outcomes over a fixed follow-up time. Covariates are either instruments (X1 and
X4), risk factors for the outcome (X2 and X5), or confounders (X3, X6, X7, X8). X7 and X8 are
strongly associated with both treatment and outcome but very rare, to mimic few patients treated
contrary to prediction. Some parameter values are set to 1 (no association) for the tables sepa-
rating ‘‘last resort’’ treatment from ‘‘treatment withheld.’’
b Odds ratio for the relation between the covariate and treatment T; parameters are for
log(ORT).
c For equations, see text.
d Rate ratio for the relation between the covariate and the outcome Y; parameters are for
log(RRY).
e ‘‘Last resort’’ treatment if random uniform number[c – p(TjX1–X6)]; c was chosen so that the
prevalence of X7 was close to 0.01.
f Approximate numbers.
g ‘‘Treatment withheld’’ if random uniform number [p(TjX1–X6)  d]; d was chosen so that the
prevalence of X8 was close to 0.01.
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based on a model including treatment and 4 indicator vari-
ables for PSX1–X6 quintiles 2–5.
In addition to these 2 PS implementations based on the
assumption of uniform effects, we analyzed the data using 3
different approaches that do not rely on this assumption.
First we combined the 5 PSX1–X6 quintile-specific treatment
effect estimates based on the standardized mortality ratio—
that is, using weights that reflect the distribution of treated
patients over the quintiles as the standard. We then tried
to find untreated matches for every treated patient based
on the estimated PSX1–X6 (1:1 individual matching). We
used 5-digit to 1-digit matching: starting with a very narrow
caliper of the PSX1–X6 (60.000005) to find an untreated
match for every treated observation without replacement
and gradually increasing the width of the caliper up
to 60.05 if no match could be found (18). Within the
matched data set, we estimated the unconfounded treatment
effect without taking matching into account. This approach
is commonly used and valid, though it is slightly less effi-
cient than taking matching into account (19). Both the
standardized mortality ratio method and matching as we
implemented it result in an estimate of a causal treatment
effect in the treated, in the presence of nonuniform treatment
effects (13).
Finally, we analyzed the data using inverse probability
of treatment weighting (IPTW). IPTW creates a pseudo-
population in which the association between covariates
and treatment is removed by weighting each observation
by the inverse of the probability of receiving the actual
treatment. To end up with a sum of weights close to the size
of the original study population, we used stabilized
weights—that is, we multiplied the IPTW weights by the
marginal prevalence of the treatment actually received (20).
We used a (conservative) robust variance estimation. IPTW
produces an estimate of a causal treatment effect in the
population in the presence of nonuniform treatment effects
(13, 20).
PS trimming. All of the above analyses were first con-
ducted without any restriction of the PS range. We then
restricted the analysis to observations within a PS range that
was common to both treated and untreated persons—that is,
by excluding all patients in the nonoverlapping parts of the
PS distribution (see Figure 2). Individual matching on the
PS also effectively resulted in a PS range that is common
to treated and untreated persons.
We then applied additional asymmetric PS trimming in
order to exclude those patients who were treated most con-
trary to prediction. We assessed 3 different cutpoints corre-
sponding to the 1st and 99th percentiles, the 2.5th and 97.5th
percentiles, and the 5th and 95th percentiles of the PS dis-
tribution in the treated and untreated patients, respectively.
Stratification into quintiles and matching were performed
after trimming.
RESULTS
In Table 2, we present the mean number of observations
and mean incidence rates in treated and untreated persons,
as well as the corresponding rate ratio from the simulated
data sets, according to a combination of the PSX1–X6 percen-
tiles in treated and untreated patients. At the lower end of
the PSX1–X6 range (up to the 5th percentile), percentiles are
derived from the distribution of PSX1–X6 in the treated. All
other percentiles, including those at the high end of the
distribution, are derived from the distribution of PSX1–X6
in the untreated. This approach allows us to concentrate
on the patients treated contrary to prediction (which would
otherwise be swamped by patients treated according to pre-
diction). It also leads to untreated patients below the 0th
percentile and treated patients above the 100th percentile.
The first set of rows in Table 2 is based on the ‘‘last resort
treatment’’ hypothesis, in which very sick patients receive
a treatment contrary to the prediction of no treatment; it
mimics the results presented in Table 2 of the Kurth et al.
paper (8). Added to the monotonic decrease of incidence rates
in both treated and untreated persons with decreasing PSX1–X6,
the presence of the unmeasured covariate X7 leads to ‘‘abnor-
mally’’ high incidence rates in the treated with low PSX1–X6.
Because we know that the true rate ratio is 2.0, the higher rate
ratios are confounded by X7. There is some residual con-
founding despite stratification on narrow PSX1–X6 strata, even
at the high end of PSX1–X6 (e.g., for the 99th–100th percentile,
rate ratio (RR) ¼ 2.14). The maximum rate ratio in any stra-
tum is less extreme than the most extreme stratum-specific














Figure 2. Schematic of asymmetric range restriction. PS, propensity score.
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The second set of rows in Table 2 is based on the ‘‘treat-
ment withheld’’ hypothesis, in which a very frail patient
does not receive a treatment as expected because of severe
disability and/or multiple concurrent medical conditions.
It mimics the results presented by Lunt et al. (9) in their
Table 4. Added to the monotonic increase of incidence
rates in both treated and untreated persons with increasing
PSX1–X6, the presence of the unmeasured covariate X8 leads
to ‘‘abnormally’’ high incidence rates in the untreated with
high PSX1–X6. This pattern is more difficult to detect be-
cause the increase of incidence rates in the untreated over
PSX1–X6 remains monotonic. High incidence rates in the
untreated patients lead to enough confounding to reverse
the direction of the association, resulting in apparently
‘‘protective’’ effect estimates confounded by X8. The min-
imum rate ratio in any stratum is less extreme than the most
extreme stratum-specific rate ratio reported by Lunt et al.
(9) (RR ¼ 0.24).
The bottom set of rows in Table 2 combines the ‘‘last
resort treatment’’ with the ‘‘treatment withheld’’ hypothesis.
These simulations show both overestimated rate ratios in the
lowest PSX1–X6 strata and underestimated rate ratios in the
highest PSX1–X6 strata.
In Table 3, we present the treatment effect estimates ob-
tained with various restrictions of the PSX1–X6 under the
‘‘last resort treatment’’ hypothesis. Note that the true rate
ratio equals 2.0 and that all PS analyses presented rely ex-
clusively on control for the measured covariates X1–X6. The
main confounding is due to measured covariates (crude
RR ¼ 3.52 vs. RR ¼ 2.13 based on the outcome model
for a treatment prevalence of 0.2). There is, however, some
uncontrolled confounding due to the unmeasured X7. The
confounding by X7 is not strong despite its strong associa-
tions with both treatment and outcome because the preva-
lence of X7 ¼ 1 is only 0.01 (Table 1).
Bias due to the unmeasured confounder X7 is reduced by
asymmetric PS trimming in most implementations of the PS
(the rate ratio moves closer to the true value of 2.0 and the
mean squared error gets smaller). The exception is PS
matching, where bias is constant (p(T ¼ 1) ¼ 0.2) or in-
creases with increasing range restrictions (p(T¼ 1) ¼ 0.05).
PS matching provides the least bias without restriction,
however, and remains among the least biased implementa-
tions with a 5–95 range restriction. With a lower prevalence
of the treatment (p(T ¼ 1) ¼ 0.05), IPTW becomes most
biased without range restriction. A lower prevalence of
treatment leads to more extreme weights in the patients
who receive treatment contrary to prediction. Given the
increase in variance and the bias reduction following
increasing trimming, the effect on the coverage of the
95% confidence interval is very pronounced for most
implementations.
In Table 4, we present the treatment effect estimates ob-
tained with various restrictions of the PSX1–X6 under the
‘‘treatment withheld’’ hypothesis. The unmeasured con-
founding due to X8 is stronger than the one by X7. It leads
to a rate ratio of 1.3 based on control for measured cova-
riates. Consequently, the effects of trimming are more pro-
nounced in this setting, monotonic, and similar for all PS
implementations. The effects of unmeasured confounding
due to X8 are most pronounced for PS matching with an
unrestricted rate ratio of 1.2 (p(T ¼ 1) ¼ 0.2).
When combining the 2 hypotheses (Table 5), asymmetric
PS trimming again leads to reduction of bias caused by the
unmeasured confounders with all PS implementations. In-
terestingly enough, increasing restrictions lead to increasing
reduction of bias with all implementations except IPTW.
With IPTW, there is a reduction of bias with restriction up
to the 2.5–97.5 level, but further restriction to the 5–95 level
increases rather than decreases bias.
DISCUSSION
We simulated data sets to mimic treatment effect hetero-
geneity in 2 separate published clinical studies under the
assumption that such heterogeneity is due to unmeasured
confounding by patient frailty. Our simulation study shows
that under this assumption, increasing asymmetric PS trim-
ming can increase the validity of the treatment effect esti-
mates. This increase in validity was observed with most of
the different PS implementations and over all of the scenarios
assessed in the simulations.
How can we detect unmeasured confounding by frailty?
Sensitivity of treatment effects to the approach of estima-
tion, especially very different results from untrimmed
IPTW, raised caution in the examples cited (8, 9). ‘‘Last
resort treatment’’ and ‘‘treatment withheld’’ will lead to
apparent heterogeneity of treatment effect estimates in the
opposite ends of the overlapping PS distribution. This het-
erogeneity could easily be missed by stratifying the data into
broad PS categories, such as quintiles. The heterogeneity
becomes apparent, however, if one stratifies the data finely
by PS at both ends of the PS distribution. Disadvantages of
stratifying by broad percentile categories such as quintiles
have been pointed out in other settings (21). Combining the
lower percentiles from the treated patients and the higher
percentiles from the untreated patients into a single ‘‘per-
centile’’ is an idea proposed previously by Stürmer et al.
(10). Although some variability will occur by chance, trends
such as those reported (8, 9) should raise caution.
We are aware of few published implementations of PS
range restrictions (8, 22, 23). Here we assessed the perfor-
mance of asymmetric PS trimming (10) when the treatment
effect is homogeneous. We observed some differences be-
tween different methods of using the PS to control con-
founding. PS matching was least affected by bias due to
unmeasured frailty that led to ‘‘last resort treatment.’’ This
result can be explained by the fact that the treatment effect
in the treated patients estimated by PS matching is based on
few matched sets with very low PS’s. Estimating the treat-
ment effect in the treated patients thus guards against major
bias due to ‘‘last resort’’ treatment, even without trimming.
Without trimming, however, estimating the treatment effect
in the treated is more susceptible to bias due to ‘‘treatment
withheld.’’ In the scenario with both ‘‘last resort treatment’’
and ‘‘treatment withheld,’’ trimming IPTW provided the
least correction of uncontrolled confounding and increasing
trimming did not monotonically lead to reduced bias. This
result is in contrast to all other PS methods and scenarios
that we assessed.
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It was difficult to mimic the results presented by Kurth
et al. (8) and Lunt et al. (9) in simulations. The difficulty
relates to the hypothesized phenomena being concentrated
within a few people in the extremes of the PS distribution.
With our 2-stage process, which first calculates the proba-
bility of intended treatment given the measured covariates to
assign our frailty covariates and then assumes strong asso-
ciations between the frailty covariates and both actual treat-
ment (odds ratio ¼ 10) and outcome (RR ¼ 10), we came
close. Nevertheless, the treatment effect heterogeneity in
our simulation study is still less extreme than the heteroge-
neity observed in published clinical studies (8, 9). Owing to
this concentration of the effect in the extremities of the PS
distribution, other methods that have been proposed to deal
with unmeasured confounders in pharmacoepidemiology
(e.g., 24–28) are likely to not perform well in this setting,
even if a measure for frailty were available.
Asymmetric trimming does not always lead to bias re-
duction with IPTW. With unmeasured confounding at both
ends of the PS distribution (Table 5), the 5–95 trimmed
estimate is slightly more biased than the 2.5–97.5 trimmed
estimate. We do not have an explanation for this observa-
tion, and we encourage more research into the behavior of
IPTW in the presence of unmeasured confounders such as
frailty and the value of trimming the population to reduce
such bias. Reestimation of PS within the trimmed popula-
tion slightly alleviated but did not suppress this problem
(e.g., RR ¼ 2.06 for 5–95 trimming vs. RR ¼ 2.11 for
p(T ¼ 1) ¼ 0.2), while results for all other scenarios
assessed were virtually identical.
Because IPTW estimates the treatment effect in the
whole population, it should only be implemented if every-
one in the study has the potential to be treated. Cole and
Hernán (29) have proposed truncation of IPTW to improve
the trade-off between variance and residual confounding
by measured covariates. Thus, truncation is not intended
to reduce bias due to unmeasured confounders, nor does it
result in bias reduction in this setting (data not shown).
Trimming by the absolute value of the PS has recently
been proposed to address lack of PS overlap and to reduce
Table 2. Mean Incidence Rates and Rate Ratios as a Function of Estimated Asymmetric Propensity Score
Percentiles From 1,000 Simulated Data Sets in the Presence of Unmeasured Confounding Due to ‘‘Last Resort
Treatment’’ and ‘‘Treatment Withheld’’
PS ‘‘Percentile’’a





No. IRc No. IRc No. IRc No. IRc
‘‘Last resort treatment’’
<0d 63 11 261 12
0–1 19 133 561 22 6.68 4 117 635 24 5.51
1–2.5 29 188 528 34 5.85 7 181 685 38 5.07
2.5–5 49 219 659 45 5.04 12 244 771 53 4.75
5–25 18 207 201 52 4.58 3 231 117 59 4.68
25–50 242 160 2,007 67 2.40 62 287 2,283 81 3.56
50–75 451 221 2,010 108 2.06 112 259 2,376 120 2.17
75–95 719 360 1,608 172 2.10 182 399 1,901 190 2.10
95–97.5 163 514 201 256 2.06 42 579 238 282 2.09
97.5–99 129 607 121 301 2.10 34 673 143 335 2.06
99–100 137 834 80 406 2.14 36 949 95 455 2.15
>100d 5 1,679 1 1,772
‘‘Treatment withheld’’
<0d 91 6 321 10
0–1 19 33 718 15 2.48 4 39 705 19 2.08
1–2.5 29 54 601 27 2.18 7 66 712 32 2.13
2.5–5 49 79 683 40 2.06 12 96 813 47 2.12
5–25 2 99 19 44 2.54 1 97 44 48 2.30
25–50 239 136 1,914 66 2.07 57 151 2,160 74 2.06
50–75 474 222 2,014 108 2.06 117 242 2,378 119 2.04
75–95 767 367 1,611 183 2.01 188 408 1,903 233 1.76
95–97.5 160 591 201 554 1.10 41 618 238 526 1.20
97.5–99 114 830 121 1,058 0.81 31 777 143 803 1.00
99–100 92 1,623 80 2,348 0.71 29 1,296 95 1,673 0.80
>100d 2 5,662 1 4,726
Table continues
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the variance of an IPTW estimator of the average treat-
ment effect (30). Crump et al. (30) proposed a selection
method that maximizes precision and concluded that
a simple rule of thumb excluding all observations outside a
PS range of 0.1–0.9 is a good approximation to maximize
precision.
Real treatment effect heterogeneity is another plausible
explanation for nonuniform treatment effects. Treatment
may be more beneficial and less harmful in patients most
likely to be treated because they have the strongest indica-
tions and the fewest contraindications, and vice versa. If
treatment effect heterogeneity is real rather than caused by
unmeasured confounders, then methods of PS implementa-
tion that do not assume uniform treatment effects should be
used and trimming will limit generalizability. Separate anal-
yses after trimming may provide a more meaningful esti-
mate in the patients where there is equipoise, however, and
highlight the difficulties in reliably estimating the treatment
effect in patients with reduced equipoise. In the study by
Kurth et al. (8), thrombolysis may have been the cause of the
increased mortality observed in a subgroup of patients de-
fined by their low probability of receiving thrombolysis. In
contrast, it is not plausible that treatment with biologics
would prevent 75% of all deaths in a subgroup of patients
defined by a high probability of receiving biologics in the
study by Lunt et al. (9).
Because the data cannot distinguish bias caused by unmea-
sured confounders from real treatment effect heterogeneity,
the validity benefit of any range restriction is arguable. Any
data excluded from primary analyses by trimming should
be presented for readers to evaluate, along the lines of our
Table 2. Such a table will illuminate the nature of the pop-
ulation to which the treatment effect estimate based on PS
range restrictions applies. After range restriction, these esti-
mates will not be causal in the sense that they do not apply to
any clearly defined population, such as all treated patients,
anymore. Thus, there will be a trade-off between validity and
estimating the treatment effect in a clearly defined population.
The conclusions of all simulation studies are limited to
the scenarios assessed. We explicitly simulated our data sets
so that the treatment effect estimate based on restricting the
range to the 5th–95th percentiles was not unbiased, to avoid
the false impression that this arbitrary cutpoint will elimi-
nate bias caused by unmeasured confounders. Misspecifica-
tion of the PS model in addition to the one due to the
unmeasured confounders in persons treated contrary to
prediction (e.g., by additional unmeasured confounders or
misspecification of measured covariates) could affect the
performance of trimming. The interpretation of results
following asymmetric PS trimming will depend on the ob-













<0d 61 11 261 12
0–1 19 125 550 21 6.75 5 103 627 22 5.25
1–2.5 29 173 516 31 5.99 7 159 651 35 4.87
2.5–5 49 199 650 41 5.01 12 219 754 49 4.65
5–25 21 200 238 48 4.84 3 238 150 55 4.75
25–50 248 148 2,013 64 2.35 65 261 2,308 77 3.44
50–75 466 212 2,013 104 2.05 117 241 2,375 114 2.12
75–95 752 349 1,611 173 2.03 188 389 1,900 222 1.76
95–97.5 158 562 201 500 1.16 41 591 238 500 1.21
97.5–99 112 778 121 978 0.82 31 742 143 760 1.01
99–100 91 1,518 80 2,197 0.71 29 1,236 95 1,592 0.80
>100d 2 5,219 1 4,170
Abbreviations: IR, incidence rate; PS, propensity score; RR, rate ratio.
a Asymmetric PS percentiles according to PS distribution in treated and untreated persons separately (to allow
closer assessment of persons treated contrary to prediction). Percentiles between 0 and 5 are derived from the PS
distribution in the treated patients; all other percentiles are derived from the PS distribution in the untreated patients.
b Controlled for measured covariates based on PS stratification; inconsistencies with the incidence rates in the
treated and untreated are due to rounding.
c Per 1,000 person-years (repeated events).
d Untreated patients in the <0 asymmetric PS percentile stratum are those with a lower PS than the lowest one
observed in the treated patients (nonoverlap). Treated patients in the >100 asymmetric PS percentile stratum are
those with a higher PS than the highest one observed in the untreated patients (nonoverlap).
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Table 3. Mean Rate Ratios, Empirical Variance, and Percent Coverage of 95% Confidence Intervals From 1,000
Simulated Data Sets in the Presence of Unmeasured Confounding Due to ‘‘Last Resort Treatment’’ Without or With
Asymmetric Trimming of the Propensity Score According to Analytic Strategy (True RR ¼ 2.0)
PS Implementation
and Trimming Range
Treatment Prevalence 5 0.2 Treatment Prevalence 5 0.05
RR Variancea MSEb Coveragec RR Variancea MSEb Coveragec
Crude 3.52 0.003 0.320 0.0 3.69 0.009 0.378 0.0
True outcome model 2.01 0.003 0.003 95.0 2.01 0.007 0.007 94.1
Outcome model (X1–X6)
d 2.13 0.003 0.007 79.6 2.20 0.008 0.016 76.3
PS analysesd
PS continuous
Unrestricted 2.15 0.004 0.009 74.0 2.25 0.009 0.022 69.2
Restricted
0–100 2.15 0.004 0.009 74.3 2.25 0.009 0.022 68.1
1–99 2.13 0.004 0.008 80.2 2.21 0.010 0.018 76.9
2.5–97.5 2.11 0.004 0.007 85.7 2.21 0.011 0.020 77.0
5–95 2.07 0.005 0.006 90.9 2.21 0.013 0.021 82.3
PS quintiles (Mantel-
Haenszel)
Unrestricted 2.28 0.003 0.020 35.8 2.42 0.008 0.043 36.0
Restricted
0–100 2.27 0.003 0.019 39.2 2.40 0.008 0.040 39.0
1–99 2.19 0.004 0.011 66.5 2.30 0.009 0.027 62.0
2.5–97.5 2.14 0.004 0.009 78.0 2.27 0.010 0.025 70.7
5–95 2.09 0.005 0.007 88.1 2.24 0.012 0.024 77.8
PS quintiles (standardized
mortality ratio)
Unrestricted 2.26 0.004 0.019 42.3 2.40 0.008 0.040 38.8
Restricted
0–100 2.25 0.004 0.017 47.4 2.38 0.008 0.037 41.8
1–99 2.16 0.004 0.009 75.2 2.28 0.009 0.025 65.6
2.5–97.5 2.12 0.004 0.007 84.3 2.25 0.010 0.023 73.1
5–95 2.08 0.005 0.006 90.4 2.22 0.012 0.022 79.8
PS matching
Unrestricted 2.08 0.005 0.006 91.7 2.18 0.018 0.024 90.3
Restricted
0–100 2.08 0.005 0.006 91.8 2.18 0.018 0.024 90.4
1–99 2.08 0.006 0.007 91.3 2.20 0.022 0.029 90.3
2.5–97.5 2.08 0.007 0.008 93.5 2.22 0.025 0.034 90.1
5–95 2.06 0.008 0.008 93.7 2.23 0.030 0.039 91.2
Inverse probability of
treatment weighting
Unrestricted 2.26 0.005 0.019 64.3 2.50 0.019 0.065 66.7
Restricted
0–100 2.24 0.005 0.017 68.4 2.44 0.018 0.055 74.3
1–99 2.25 0.005 0.018 65.8 2.48 0.018 0.060 68.6
2.5–97.5 2.21 0.005 0.014 75.4 2.46 0.018 0.057 72.0
5–95 2.12 0.005 0.009 88.0 2.40 0.020 0.050 76.3
Abbreviations: MSE, mean squared error; PS, propensity score; RR, rate ratio.
a Variance of treatment effect estimates [log(RR)] over 1,000 simulated data sets.
b Mean of [log(RR) – log(2.0)]2 over 1,000 simulated data sets.
c Percentage of simulated studies in which the 95% confidence interval includes the true value (RR ¼ 2.0).
d Outcome and PS models including all measured covariates X1–X6 but not including unmeasured covariate X7.
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Table 4. Mean Rate Ratios, Empirical Variance, and Percent Coverage of 95% Confidence Intervals From 1,000
Simulated Data Sets in the Presence of Unmeasured Confounding Due to ‘‘Treatment Withheld’’ Without or With
Asymmetric Trimming of the Propensity Score According to Analytic Strategy (True RR ¼ 2.0)
PS Implementation
and Trimming Range
Treatment Prevalence 5 0.2 Treatment Prevalence 5 0.05
RR Variancea MSEb Coveragec RR Variancea MSEb Coveragec
Crude 2.85 0.007 0.130 0.1 2.93 0.016 0.157 4.4
True outcome model 2.00 0.003 0.003 94.0 2.00 0.007 0.007 94.1
Outcome model (X1–X6)
d 1.30 0.006 0.193 0.0 1.34 0.013 0.182 1.1
PS analysesd
PS continuous
Unrestricted 1.31 0.007 0.191 0.0 1.38 0.023 0.171 5.9
Restricted
0–100 1.31 0.007 0.190 0.0 1.41 0.019 0.146 5.9
1–99 1.53 0.006 0.078 1.7 1.50 0.014 0.099 14.0
2.5–97.5 1.75 0.006 0.004 38.5 1.63 0.014 0.059 39.3
5–95 1.95 0.005 0.006 91.0 1.75 0.014 0.033 71.9
PS quintiles (Mantel-
Haenszel)
Unrestricted 1.52 0.008 0.086 2.1 1.61 0.016 0.066 23.9
Restricted
0–100 1.50 0.007 0.092 1.5 1.58 0.015 0.073 19.6
1–99 1.65 0.006 0.045 11.7 1.63 0.012 0.056 33.8
2.5–97.5 1.82 0.005 0.015 59.7 1.71 0.013 0.040 56.6
5–95 1.98 0.005 0.005 91.8 1.80 0.014 0.027 77.5
PS quintiles (standardized
mortality ratio)
Unrestricted 1.46 0.009 0.109 1.3 1.60 0.016 0.070 22.4
Restricted
0–100 1.45 0.008 0.116 1.1 1.57 0.015 0.077 19.0
1–99 1.59 0.006 0.060 6.7 1.62 0.013 0.059 30.9
2.5–97.5 1.78 0.006 0.020 49.4 1.70 0.013 0.042 53.6
5–95 1.97 0.005 0.006 91.3 1.79 0.014 0.028 76.7
PS matching
Unrestricted 1.22 0.008 0.255 0.0 1.28 0.033 0.250 9.5
Restricted
0–100 1.22 0.008 0.254 0.0 1.28 0.033 0.249 9.4
1–99 1.45 0.008 0.113 1.4 1.49 0.030 0.127 33.3
2.5–97.5 1.69 0.008 0.037 38.5 1.63 0.031 0.080 60.7
5–95 1.94 0.008 0.009 89.2 1.77 0.034 0.054 81.7
Inverse probability of
treatment weighting
Unrestricted 1.31 0.007 0.192 0.0 1.57 0.014 0.076 50.2
Restricted
0–100 1.29 0.007 0.203 0.0 1.52 0.013 0.093 38.6
1–99 1.62 0.005 0.052 19.3 1.69 0.013 0.045 70.4
2.5–97.5 1.82 0.005 0.014 75.2 1.77 0.013 0.029 83.2
5–95 1.99 0.005 0.005 94.5 1.85 0.014 0.022 91.1
Abbreviations: MSE, mean squared error; PS, propensity score; RR, rate ratio.
a Variance of treatment effect estimates [log(RR)] over 1,000 simulated data sets.
b Mean of [log(RR) – log(2.0)]2 over 1,000 simulated data sets.
c Percentage of simulated studies in which the 95% confidence interval includes the true value (RR ¼ 2.0).
d Outcome and PS models including all measured covariates X1–X6 but not including unmeasured covariate X7.
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Table 5. Mean Rate Ratios, Empirical Variance, and Percent Coverage of 95% Confidence Intervals From
1,000 Simulated Data Sets in the Presence of Unmeasured Confounding Due to ‘‘Last Resort Treatment’’ and
‘‘Treatment Withheld’’ Without or With Asymmetric Trimming of the Propensity Score According to Analytic Strategy
(True RR ¼ 2.0)
PS Implementation
and Trimming Range
Treatment Prevalence 5 0.2 Treatment Prevalence 5 0.05
RR Variancea MSEb Coveragec RR Variancea MSEb Coveragec
Crude 2.86 0.006 0.131 0.0 2.98 0.015 0.169 3.6
True outcome model 2.00 0.003 0.003 95.5 1.99 0.007 0.007 93.7
Outcome model (X1–X6)
d 1.39 0.006 0.142 0.0 1.45 0.014 0.124 5.0
PS analysesd
PS continuous
Unrestricted 1.38 0.007 0.149 0.0 1.46 0.022 0.128 10.6
Restricted
0–100 1.38 0.007 0.149 0.0 1.49 0.018 0.109 12.0
1–99 1.63 0.006 0.049 9.6 1.62 0.015 0.061 33.4
2.5–97.5 1.85 0.006 0.012 69.3 1.77 0.015 0.032 66.2
5–95 2.01 0.005 0.005 93.6 1.90 0.015 0.018 85.9
PS quintiles (Mantel-
Haenszel)
Unrestricted 1.60 0.007 0.057 6.3 1.72 0.016 0.041 44.7
Restricted
0–100 1.59 0.007 0.062 4.8 1.69 0.015 0.046 40.8
1–99 1.75 0.006 0.024 35.2 1.77 0.014 0.031 61.6
2.5–97.5 1.92 0.005 0.007 83.3 1.86 0.014 0.021 78.8
5–95 2.04 0.005 0.005 92.3 1.95 0.015 0.016 88.1
PS quintiles (standardized
mortality ratio)
Unrestricted 1.53 0.008 0.084 3.1 1.69 0.016 0.047 39.4
Restricted
0–100 1.51 0.008 0.089 2.1 1.67 0.015 0.052 34.5
1–99 1.67 0.006 0.039 17.3 1.74 0.014 0.035 57.2
2.5–97.5 1.87 0.006 0.011 73.2 1.83 0.014 0.023 76.0
5–95 2.02 0.005 0.005 93.4 1.93 0.015 0.016 88.0
PS matching
Unrestricted 1.28 0.009 0.215 0.0 1.35 0.036 0.202 15.0
Restricted
0–100 1.28 0.009 0.214 0.0 1.35 0.035 0.201 15.0
1–99 1.53 0.008 0.084 5.1 1.59 0.035 0.096 48.3
2.5–97.5 1.78 0.008 0.023 59.3 1.76 0.037 0.059 60.7
5–95 1.99 0.008 0.008 93.2 1.90 0.040 0.045 81.7
Inverse probability of
treatment weighting
Unrestricted 1.49 0.008 0.096 8.9 1.90 0.019 0.023 92.5
Restricted
0–100 1.48 0.008 0.101 6.7 1.86 0.019 0.026 89.9
1–99 1.83 0.006 0.014 79.5 2.05 0.019 0.019 94.0
2.5–97.5 2.02 0.005 0.005 96.4 2.13 0.019 0.022 92.9
5–95 2.11 0.005 0.008 90.2 2.18 0.020 0.026 90.7
Abbreviations: MSE, mean squared error; PS, propensity score; RR, rate ratio.
a Variance of treatment effect estimates [log(RR)] over 1,000 simulated data sets.
b Mean of [log(RR) – log(2.0)]2 over 1,000 simulated data sets.
c Percentage of simulated studies in which the 95% confidence interval includes the true value (RR ¼ 2.0).
d Outcome and PS models including all measured covariates X1–X6 but not including unmeasured covariate X7.
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We conclude that one plausible explanation for the very
heterogeneous treatment effects on mortality presented by
Kurth et al. (8) and Lunt et al. (9), unmeasured confounding
by frailty, can be reduced by increasing asymmetric trim-
ming of the PS. Under this assumption, trimming enhances
validity. The ability to trim outliers based on a single vari-
able that summarizes confounding from other, measured
variables is an important advantage of PS’s compared with
conventional outcome models.
Because real treatment effect heterogeneity cannot be
excluded as an alternative explanation, asymmetric PS trim-
ming should be used judiciously, perhaps as a sensitivity
analysis. To inform interpretation, investigators should pre-
sent data on the outcomes in treated and untreated patients
finely stratified according to the PS distribution for treated
patients at the lower end and the PS distribution for un-
treated patients at the higher end.
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